Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study (NCT06409689) | Clinical Trial Compass
RecruitingNot Applicable
Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study
China80 participantsStarted 2024-06-01
Plain-language summary
Identifying the lowest effective opioid dose that achieves rapid pain relief while minimizing side effects is a principal objective in postoperative multimodal analgesia strategies. This study aims to determine the optimal analgesic regimen and dosage by assessing the clinical efficacy of oliceridine for postoperative pain management. It also evaluates oliceridine's contribution to accelerated postoperative recovery, examining aspects such as postoperative pulmonary complications, gastrointestinal function, nausea and vomiting, cognitive function, and emotional distress. Furthermore, the study integrates microbiomics and metabolomics to investigate the underlying molecular mechanisms by which oliceridine promotes rapid postoperative recovery. This research will broaden the clinical data and potential applications of oliceridine, addressing gaps in the field and enhancing practical knowledge. Moreover, this is the first time a clinical study combining multiple omics approaches will provide a comprehensive theoretical foundation for its clinical benefits.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. ASA grades 1-2
✓. Age \> 18 years and \< 70 years
✓. Laparoscopic upper abdominal surgery under general anesthesia is planned, and the operation time is not more than 4 hours